Celldex Therapeutics (NASDAQ: CLDX) reported positive topline results from two Phase 3 trials of barzolvolimab in patients with chronic spontaneous ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE